Exploratory Outcomes News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Exploratory Outcomes. Real-time updates on events, politics, business and more.

Pamrevlumab for Idiopathic Pulmonary Fibrosis

May 19, 2024

This randomized clinical trial compares the efficacy and safety of pamrevlumab vs placebo for patients with idiopathic pulmonary fibrosis.

United States San Diego Eteläuomen Läi University Of California San Diego South Korea Roche Genentech

Source: jamanetwork.com

Biogen Inc.: New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

October 13, 2021

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower

United States United Kingdom John Foley Maha Radhakrishnan Charles Weissmann Walter Gilbert

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Exploratory Outcomes News Today

Pamrevlumab for Idiopathic Pulmonary Fibrosis

Biogen Inc.: New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

Explore More Categories